These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20163014)

  • 1. [A questionnaire study on the necessity of approval for revaccination of the pneumococcal polysaccharide vaccine].
    Oishi K; Kawakami K; Nagai H; Sunakawa K; Watanabe A
    Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):5-9. PubMed ID: 20163014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.
    Nakamura A; Kawakami K; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Sep; 16(9):2292-2299. PubMed ID: 32045317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska.
    Walker FJ; Singleton RJ; Bulkow LR; Strikas RA; Butler JC
    Clin Infect Dis; 2005 Jun; 40(12):1730-5. PubMed ID: 15909258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.
    Törling J; Hedlund J; Konradsen HB; Ortqvist A
    Vaccine; 2003 Dec; 22(1):96-103. PubMed ID: 14604576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of revaccination with pneumococcal polysaccharide vaccine.
    Jackson LA; Benson P; Sneller VP; Butler JC; Thompson RS; Chen RT; Lewis LS; Carlone G; DeStefano F; Holder P; Lezhava T; Williams WW
    JAMA; 1999 Jan; 281(3):243-8. PubMed ID: 9918479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study.
    Jackson LA; Baxter R; Naleway AL; Belongia EA; Baggs J
    BMC Infect Dis; 2009 Mar; 9():37. PubMed ID: 19321001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
    Manoff SB; Liss C; Caulfield MJ; Marchese RD; Silber J; Boslego J; Romero-Steiner S; Rajam G; Glass NE; Whitney CG; Carlone GM
    J Infect Dis; 2010 Feb; 201(4):525-33. PubMed ID: 20088694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population.
    Jackson LA; Nelson JC; Whitney CG; Neuzil KM; Benson P; Malais D; Baggs J; Mullooly J; Black S; Shay DK
    Vaccine; 2006 Jan; 24(2):151-6. PubMed ID: 16122845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing pneumococcal revaccination safety among New York State Medicare beneficiaries.
    Shih A; Quinley J; Lee TK; Messina CR
    Public Health Rep; 2002; 117(2):164-73. PubMed ID: 12357001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination.
    Holmlund E; Nohynek H; Quiambao B; Ollgren J; Käyhty H
    Vaccine; 2011 Jun; 29(28):4565-75. PubMed ID: 21550374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
    Grabenstein JD; Manoff SB
    Vaccine; 2012 Jun; 30(30):4435-44. PubMed ID: 22542818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
    Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
    Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.